Husamuddin Ansari
Ophthalmology · Boston, MANPI 1699781229
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,500 of the $26,835 with a category attached, or 65.2%. 16 manufacturers reported payments, led by AbbVie at 40.7% of the total. Reporting peaked in 2019 at $13,585 and has fallen 86.6% since, to $1,818 in 2025. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $239.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- NEW World Medical,inc.$8K
- Ivantis, Inc$6K
- Alcon$446
- Sight Sciences, Inc.$348
- Glaukos Corporation$340
- plus $721 from 10 others
Across 93 payments — averaging $2187.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$187K
- Ivantis, Inc$11K
- NEW World Medical,inc.$5K
What the payments were for
- Consulting fees$17,50065%
- Speaking & faculty fees$3,00011%
- Travel & lodging$1,4015%
- Food & beverage$4,79918%
- Gifts$1351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $10,913 |
| NEW World Medical,inc. | 9 | $8,315 |
| Ivantis, Inc | 6 | $5,753 |
| Alcon | 8 | $446 |
| Sight Sciences, Inc. | 6 | $348 |
| Glaukos Corporation | 3 | $340 |
| Aerie Pharmaceuticals, Inc. | 4 | $282 |
| Rxsight Inc | 1 | $144 |
| Tarsus Pharmaceuticals, Inc. | 3 | $110 |
| Opsens Inc. | 1 | $44 |
| Novartis | 2 | $39 |
| Carl Zeiss Meditec, Inc. | 1 | $26 |
| Thea Pharma Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $18 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$6,702
- Kahook Dual Blade$6,702
- Hydrus$5,613
- XEN$2,270
- DURYSTA$875
- XEN GLAUCOMA TREATMENT SYSTEM$392
- OMNI(R) SURGICAL SYSTEM (US)$289
- iDoseTR$212
- Streamline Surgical System$202
- SION SURGICAL INSTRUMENT$147
- Rocklatan$145
- RXSIGHT CONTACT LENS$144
- RXSIGHT INJECTOR CARTRIDGE$144
- RXSIGHT INJECTOR HANDPIECE$144
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$144
- LIGHT ADJUSTABLE LENS (LAL)$144
- iStent Trabecular Micro-Bypass Stent System$125
- iStent inject Trabecular Micro-Bypass Stent System$125
How this compares
$26,835 in reported general payments places this provider in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 293 | $158,678 |
| CombiganBrimonidine Tartrate/Timolol | 139 | $58,139 |
| RhopressaNetarsudil Mesylate | 99 | $58,125 |
| Prednisolone Acetate | 815 | $55,653 |
| RocklatanNetarsudil Mesylat/Latanoprost | 95 | $47,878 |
| Alphagan PBrimonidine Tartrate | 102 | $45,605 |
| VyzultaLatanoprostene Bunod | 63 | $36,536 |
| Brinzolamide | 155 | $31,072 |
| RestasisCyclosporine | 32 | $30,814 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 50 | $25,308 |
| Latanoprost | 1,903 | $23,796 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 78 | $19,532 |
| Timolol Maleate | 978 | $15,869 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 78 | $15,733 |
| Travoprost | 86 | $15,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $10,913 | $293,237566 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $282 | $106,003194 claims |
| AlconSimbrinza | $446 | $25,30850 claims |
| NovartisTravatan Z | $39 | $10,53218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.